CONTACT US
Home > Inhibitors/Agonists>COX> > Naproxen
22204-53-1-Naproxen Naproxen

Naproxen

For research use only. Not for therapeutic Use.

  • CAT Number: I002699
  • CAS Number: 22204-53-1
  • Molecular Formula: C14H14O3
  • Molecular Weight: 230.3
  • Purity: ≥95%
Inquiry Now
Related products: Terpinyl Acetate     Demethyleneberberine     Efetaal    
Research Areas: Metabolic Disease Research     Oxidative Stress and Inflammation    

Naproxen(CAT: I002699) is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzyme cyclooxygenase (COX), specifically COX-1 and COX-2. By blocking COX enzymes, naproxen reduces the production of prostaglandins, which are involved in inflammation, pain, and fever. This leads to its analgesic, anti-inflammatory, and antipyretic effects. Naproxen is commonly used to treat various inflammatory conditions, including arthritis, gout, and musculoskeletal injuries. It is available in different formulations and dosages, including prescription and over-the-counter options. It’s important to note that naproxen, like other NSAIDs, may have potential side effects and should be used under medical supervision.


Catalog Number I002699
CAS Number 22204-53-1
Synonyms

(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid

Molecular Formula C14H14O3
Purity ≥95%
Target COX
Solubility DMSO: ≥ 47 mg/mL
Storage Room temperature
IUPAC Name (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
InChI InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
InChIKey CMWTZPSULFXXJA-UHFFFAOYSA-N
SMILES CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
Reference

<br />
1:Enzymes Involved in Naproxen Degradation by Planococcus sp. S5. Wojcieszyńska D, Domaradzka D, Hupert-Kocurek K, Guzik U.Pol J Microbiol. 2016;65(2):177-82. PMID: 28517919<br />
2:Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis. Comi E, Lanza M, Ferrari F, Mauri V, Caselli G, Rovati LC.J Pain Res. 2017 May 4;10:1033-1043. doi: 10.2147/JPR.S132026. eCollection 2017. PMID: 28496359 Free PMC Article<br />
3:Inclusion Complexes of a New Family of Non-Ionic Amphiphilic Dendrocalix[4]arene and Poorly Water-Soluble Drugs Naproxen and Ibuprofen. Khan K, Badshah SL, Ahmad N, Rashid HU, Mabkhot Y.Molecules. 2017 May 11;22(5). pii: E783. doi: 10.3390/molecules22050783. PMID: 28492508 Free Article<br />
4:Heteroleptic silver(I) complexes with 2,2/&#39;:6/&#39;,2&Prime;-terpyridines and naproxen: DNA interaction, EGFR/VEGFR2 kinase, growth inhibition and cell cycle arrest studies. Mahendiran D, Kumar RS, Rahiman AK.Mater Sci Eng C Mater Biol Appl. 2017 Jul 1;76:601-615. doi: 10.1016/j.msec.2017.03.085. Epub 2017 Mar 15. PMID: 28482570<br />
5:Biodegradation of naproxen by freshwater algae Cymbella sp. and Scenedesmus quadricauda and the comparative toxicity. Ding T, Lin K, Yang B, Yang M, Li J, Li W, Gan J.Bioresour Technol. 2017 Apr 8;238:164-173. doi: 10.1016/j.biortech.2017.04.018. [Epub ahead of print] PMID: 28433904<br />
6:Enantioselective synthesis of (S)-naproxen using immobilized lipase on chitosan beads. Gilani SL, Najafpour GD, Heydarzadeh HD, Moghadamnia A.Chirality. 2017 Apr 19. doi: 10.1002/chir.22689. [Epub ahead of print] PMID: 28422452<br />
7:Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen. Li X, DuBois DC, Song D, Almon RR, Jusko WJ, Chen X.Drug Metab Dispos. 2017 Apr 17. pii: dmd.117.075614. doi: 10.1124/dmd.117.075614. [Epub ahead of print] PMID: 28416614<br />
8:NSAIDs for high-risk patients: none, celecoxib, or naproxen? McGettigan P, Olsen AS.Lancet. 2017 Apr 11. pii: S0140-6736(17)30980-7. doi: 10.1016/S0140-6736(17)30980-7. [Epub ahead of print] No abstract available. PMID: 28410794<br />
9:Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH.Lancet. 2017 Apr 11. pii: S0140-6736(17)30981-9. doi: 10.1016/S0140-6736(17)30981-9. [Epub ahead of print] PMID: 28410791<br />
10:Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium. Beyer A, Grohganz H, L&ouml;bmann K, Rades T, Leopold CS.Int J Pharm. 2017 Apr 6;526(1-2):88-94. doi: 10.1016/j.ijpharm.2017.04.011. [Epub ahead of print] PMID: 28392278

Request a Quote